Lisata Therapeutics
在场
Lisata Therapeutics 是一家在股票代码 LSTA (US) 下上市的公司。
高管
查看带有其 14 名主要高管的组织结构图
Lisata Therapeutics 搜索最多的简介
- David Mazzo, President, Chief Executive Officer and Director
- Steven Klosk, Director
- Heidi Henson, Director
创建提醒
跟踪 Lisata Therapeutics 的高管变动
医疗设备
Lisata Therapeutics 拥有 997 家竞争者，其中包括 Philips (荷兰)、Medtronic (爱尔兰岛) 和 Thermo Fisher Scientific (美国(美洲))。
Popular M&A news in 医疗设备
- Boston Scientific 已收购 Axonics Modulation Technologies (公布2024十一月18号).
- ShiraTronics 刚刚宣布为 66 筹款数百万美元。 (公布2024十月23号).
- Johnson & Johnson 已收购 V-Wave (公布2024十月9号).
医疗设备 行业的其他推荐联系人
消息
Lisata Therapeutics 的最新新闻稿
- Caladrius Biosciences Completes Enrollment in Phase 1b Study of CLBS201 for the Treatment of Diabetic Kidney Disease | Caladrius Biosciences, Inc.
- Caladrius Biosciences to Host Second Quarter 2022 Financial Results Conference Call on Thursday, August 4, 2022, at 4:30 p.m. Eastern Time | Caladrius Biosciences, Inc.
- Caladrius Biosciences and Cend Therapeutics Announce Publication of Pancreatic Cancer Trial Data in The Lancet Gastroenterology and Hepatology | Caladrius Biosciences, Inc.
- Caladrius Biosciences Announces Merger Partner, Cend Therapeutics, has Treated First Patient in Phase 2b Trial of CEND-1 in Collaboration with Australasian Gastro-Intestinal Cancer Trials Group | Caladrius Biosciences, Inc.
- Caladrius Biosciences to Present at the BIO International Convention 2022 | Caladrius Biosciences, Inc.
- Caladrius Biosciences and Cend Therapeutics Announce Poster Presentation at the 2022 American Society of Clinical Oncology Annual Meeting | Caladrius Biosciences, Inc.
- Press Releases | Caladrius Biosciences, Inc.
- Press Releases | Caladrius Biosciences, Inc.
- Caladrius Biosciences Provides Update on Phase 2b FREEDOM Trial of XOWNA® in Coronary Microvascular Dysfunction | Caladrius Biosciences, Inc.
- Caladrius Biosciences Announces IDMC Recommendation to Advance CLBS201 Trial for the Treatment of Diabetic Kidney Disease | Caladrius Biosciences, Inc.
- View more press releases Close
通过电子邮件
